Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (Vatalanib) antiangiogenic therapy

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4892-4900

  Koukourakis, Michael I ^a   Giatromanolaki, Alexandra ^a   Sivridis, Efthimios ^a   Gatter, Kevin C ^b,c   Trarbach, Tanja ^d   Folprecht, Gunnar ^e   Shi, Michael M ^f   Lebwohl, David ^f   Jalava, Tarja ^h   Laurent, Dirk ⁱ   Meinhardt, Gerold ^g   Harris, Adrian L ^b,c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g BAYER CORPORATION   (United States)

^h Bayer Schering Pharma Oy   (Finland)

ⁱ BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE 5; OXIDOREDUCTASE; PLACEBO; UNCLASSIFIED DRUG; VATALANIB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE LEVEL; TUMOR VOLUME;

EID: 79960433377     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2918     Document Type: Article

References (22)

1. Holbrook JJ, Liljas A, Steindel SJ, Rossman MG. Lactate dehydrogenase. Vol. 11. 3rd ed. Boyer PD, editor. The enzymes. New York: Academic Press; 1975, p. 191-292.
2. Warburg O. The metabolism of tumors. New York: R. R. Smith, Inc.; 1931.
3. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-8. (Pubitemid 35232274)
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
5. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-8.
6. Steward WP, Thomas A, Morgan B, Wiedenmann B, Bartel C, Vanhoefer U, et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;2:3556.
7. Trarbach T, Schleucher N, Tewes M, Seeber S, Junker U, Laurent D, et al. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer (CRC). ASCO Annual Meeting Proceedings. J Clin Oncol 2005;3:3605.
8. Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff RK, Lloyd K, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23:LBA3.
9. Koehne C, Bajetta E, Lin E, Van Cutsem E, Hecht J, Douillard J, et al. Results of an interim analysis of a multinational randomized, doubleblind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:3508.
10. Major P, Trarbach T, Lenz H, Kerr D, Pendergrass K, Douillard J, et al. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:3529.
11. Watine J, Friedberg B. Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin Chim Acta 2004;345:1-15. (Pubitemid 38749167)
12. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005;22:25-30. (Pubitemid 41185858)
13. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006;24:4301-8. (Pubitemid 46630788)
14. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL, Trarbach G, et al. Intratumoral lactate dehydrogenase 5 (LDH5) protein is associated with the expression of angiogenesis markers and hypoxia in patients with colorectal cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25:4107.
15. Kemeny N, Niedzwiecki D, Reichman B, Botet J, Vinciguerra V, Michaelson R, et al. Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. Cancer 1989;63:1065-9.
16. Kemeny N, Niedzwiecki D, Shurgot B, Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer 1989;63:742-7.
17. Watine J, Friedberg B. Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin Chim Acta 2004;345:1-15. (Pubitemid 38749167)
18. Díaz R, Aparicio J, Gironés R, Molina J, Palomar L, Segura A, et al. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with firstline irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 2005;5:197-202.
19. Lin JT, Wang WS, Yen CC, Liu JH, Yang MH, Chao TC, et al. Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol 2005;20:900-5.
20. Patiar S, Harris AL. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 2006;13(Suppl 1):61-75.
21. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006;66:632-7. (Pubitemid 43165922)
22. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 2007;8:1705-13.